AU2010218261B2 - Compositions and methods for visualizing and eliminating cancer stem cells - Google Patents

Compositions and methods for visualizing and eliminating cancer stem cells Download PDF

Info

Publication number
AU2010218261B2
AU2010218261B2 AU2010218261A AU2010218261A AU2010218261B2 AU 2010218261 B2 AU2010218261 B2 AU 2010218261B2 AU 2010218261 A AU2010218261 A AU 2010218261A AU 2010218261 A AU2010218261 A AU 2010218261A AU 2010218261 B2 AU2010218261 B2 AU 2010218261B2
Authority
AU
Australia
Prior art keywords
patient
prolactin
receptor antagonist
cancer cells
prolactin receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010218261A
Other languages
English (en)
Other versions
AU2010218261A1 (en
Inventor
Wen Y. Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolix Inc
Original Assignee
Oncolix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolix Inc filed Critical Oncolix Inc
Publication of AU2010218261A1 publication Critical patent/AU2010218261A1/en
Application granted granted Critical
Publication of AU2010218261B2 publication Critical patent/AU2010218261B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5756—Prolactin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010218261A 2009-02-26 2010-02-16 Compositions and methods for visualizing and eliminating cancer stem cells Ceased AU2010218261B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15562409P 2009-02-26 2009-02-26
US61/155,624 2009-02-26
PCT/US2010/024340 WO2010099003A2 (en) 2009-02-26 2010-02-16 Compositions and methods for visualizing and eliminating cancer stem cells

Publications (2)

Publication Number Publication Date
AU2010218261A1 AU2010218261A1 (en) 2011-09-01
AU2010218261B2 true AU2010218261B2 (en) 2015-08-20

Family

ID=42133705

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010218261A Ceased AU2010218261B2 (en) 2009-02-26 2010-02-16 Compositions and methods for visualizing and eliminating cancer stem cells

Country Status (9)

Country Link
US (1) US8754035B2 (enExample)
EP (1) EP2400979B1 (enExample)
JP (2) JP5963443B2 (enExample)
KR (1) KR101672401B1 (enExample)
CN (2) CN106177954A (enExample)
AU (1) AU2010218261B2 (enExample)
CA (1) CA2753804C (enExample)
IL (2) IL214545A (enExample)
WO (1) WO2010099003A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648046B2 (en) * 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
EP2576823A1 (en) * 2010-06-04 2013-04-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Constitutively active prolactin receptor variants as prognostic markers and therapeutic targets to prevent progression of hormone-dependent cancers towards hormone-independence
TW201920283A (zh) 2012-12-24 2019-06-01 美商艾伯維有限公司 催乳激素受體結合蛋白質及其用途
WO2015193417A1 (en) * 2014-06-18 2015-12-23 Prorec Bio Ab Prolactin receptor antagonists for treatment of glioblastoma
CN107198779A (zh) * 2016-11-29 2017-09-26 南京东纳生物科技有限公司 一种干细胞标记示踪及靶向导航的纳米偶联复合物及其制备方法和应用
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
WO2020011998A1 (en) * 2018-07-13 2020-01-16 Hifibio Sas Use of droplet single cell epigenome profiling for patient stratification
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058142A1 (en) * 1998-05-12 1999-11-18 Chen Wen Y Use of anti-prolactin agents to treat proliferative conditions
US20050271626A1 (en) * 2004-03-08 2005-12-08 Greenville Hospital Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
DE2616086C2 (de) 1976-04-13 1986-04-03 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin
CA2921260A1 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2001085777A2 (en) 2000-05-09 2001-11-15 Greenville Hospital System Therapeutic pore-forming peptides
KR100567718B1 (ko) * 2001-07-31 2006-04-05 화이자 프로덕츠 인크. 에스트로겐 작용제/길항제와 에스트로겐과 프로게스틴의조합을 포함하는 약학 조성물, 키트 및 방법
AU2003230750A1 (en) 2002-03-29 2003-10-13 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
RU2329274C2 (ru) 2002-09-11 2008-07-20 Фрезениус Каби Дойчланд Гмбх Способ получения производных гидроксиалкилкрахмала
MXPA05006945A (es) 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor.
US20050238628A1 (en) 2004-04-08 2005-10-27 Blau Carl A Methods for treating cancer
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
US8420665B2 (en) 2008-01-11 2013-04-16 Northwestern University Anti-cancer compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058142A1 (en) * 1998-05-12 1999-11-18 Chen Wen Y Use of anti-prolactin agents to treat proliferative conditions
US20050271626A1 (en) * 2004-03-08 2005-12-08 Greenville Hospital Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BONTENBAL M ET AL, BRITISH JOURNAL OF CANCER, 1998, Vol. 77, no. 1, pages 115-122 *
MICHELE L SCOTTI ET AL: "Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells" BREAST CANCER RESEARCH AND TREATMENT, 2008, Vol. 111, pages 241-250 *
REYNOLDS C ET AL: "EXPRESSION OF PROLACTIN AND ITS RECEPTOR IN HUMAN BREAST CARCINOMA" ENDOCRINOLOGY, 1997, Vol. 138, no. 12, pages 5555-5560 *

Also Published As

Publication number Publication date
JP2014156484A (ja) 2014-08-28
EP2400979A2 (en) 2012-01-04
CA2753804A1 (en) 2010-09-02
CA2753804C (en) 2018-03-13
WO2010099003A2 (en) 2010-09-02
AU2010218261A1 (en) 2011-09-01
US20100215577A1 (en) 2010-08-26
CN106177954A (zh) 2016-12-07
KR101672401B1 (ko) 2016-11-16
WO2010099003A3 (en) 2011-02-17
IL214545A (en) 2016-07-31
KR20110139703A (ko) 2011-12-29
IL214545A0 (en) 2011-09-27
JP5963443B2 (ja) 2016-08-03
US8754035B2 (en) 2014-06-17
JP2012519168A (ja) 2012-08-23
EP2400979B1 (en) 2015-05-20
CN102341118A (zh) 2012-02-01
IL246247A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
AU2010218261B2 (en) Compositions and methods for visualizing and eliminating cancer stem cells
EP2640412B1 (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
JP2011504361A (ja) 肝細胞癌細胞に特異的なペプチドおよびその適用
CN102134275B (zh) 表皮生长因子受体变异体
US8754031B2 (en) Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
EP2515930A1 (en) Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
WO2012048667A1 (zh) 表皮生长因子受体的外显子缺失变异体
HK1231758A1 (en) Compositions and methods for visualizing and eliminating cancer stem cells
HK1231759A1 (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
HK1189171A (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
HK1166693A (en) Compositions and methods for visualizing and eliminating cancer stem cells
KR102133205B1 (ko) PNA-pHLIP 접합체를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
EP3984547A1 (en) Peptides for the treatment of cancer
US10201610B2 (en) Interference peptides and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired